电刺激联合盆底肌训练治疗女性压力性尿失禁合并特发性逼尿肌过度活动的疗效观察

Objective To investigate the short-term efficacy of pelvic floor electrical stimulation (PFES) and pelvic floor training (PFT) for female with idiopathic detrusor overactivity (IDO) and stress urinary incontinence (SUI). Methods PFES and PFT were performed on 70 women (average age 40±7 years old) with IDO and SUI for twelve weeks. Urinary diary, International Continence In-quiring Committee's Questionnaire (ICI-Q-SF) scores were recorded and urodynamic study was per-formed before and after the treatment. Results Fifty women (71%) finally completed treatment for twelve weeks. Urinary incontinence disappeared in 8 (16%), detrusor overactivity disappeared in 10 (20 %). The leakage was not found in 6 (12 %) in leakage point pressure measurement. Moreover, the frequency of voiding (28±5 times/72 h), frequency of leakage (10±5 times/72 h), total scores of ICI-Q-SF(10±3), max detrusor uninhibited contraction pressure (18±8 cmH20) and detrusor unin-hibited contraction duration (8±3 s) were significantly lower than those before treatment (43±8 times/72 h, 20±6 times/72 h, 17±3, 27±9 cm H2O and 13±6s,P<0.01). Maximal voided vol-ume(225±48 ml), normal desired cystometric capacity (210±48 ml), maximal cystometric capacity (247±48 ml), Valsalva leak point pressure (94±11 cm H2O) and maximal urethral closure pressure (59±8 cm H2O) were significantly higher than those before treatment (159±37 ml, 141±39ml, 178±36ml, 81±15 cm H2O and 55±8 cm H2O, P<0.01). The effective rate during three months follow up was 60%, similar to time after treatment (P>0.05). Conclusions Pelvic floor electrical stimulation and pelvic floor training could be a useful therapy to treat women with IDO and SUI. It is both convenient and economical.     

肾母细胞瘤组织WT1、P53基因缺失检测

目的：对肾母细胞瘤组织WT1、P53基因缺失情况进行检测。方法：30例 散发性肾母细胞瘤组织，其中上皮优势型6例，母细胞优势型14例，间质优势型10例，采用Southern印迹分子杂交技术检测肾母细胞瘤组织WT1、P53基因缺失，并分析其与组织类型的关系。结果：2例WT1基因的缺失为间质优势型肾母细胞瘤，1例P53等位基因缺失为间变型肾母细胞瘤。结论：WT1基因缺失可能与间质优势型肾母细胞瘤的发生有关，P53基因缺失可能与间变型肾母细胞瘤的发生有关。     

氟喹诺酮类药物致肾脏严重不良反应５１例分祈

目的：了解氟喹诺酮类药物的肾脏不良反应，为临床合理用药提供资料。方法：查阅国内检索类中医药期刊，归纳有关ＦＱｓ肾脏不良反应的报道。结果：ＦＱｓ肾脏主要不良反应有血尿、间质性肾炎或急性肾功能衰竭等。结论：ＦＱｓ的肾脏严重不良反应少见，但较严重。用药期间密切观察肾功能。     

经尿道前列腺气化电切术治疗前列腺增生症的体会(附24例报告)

目的寻找恰当的前列腺增生症的治疗方法。方法采用经尿道前列腺电切术(TUEVAP)治疗前列腺增生症(BPH)24例。结果24例手术均成功,手术时间40～90分钟,膀胱冲洗液3天内转清,5天内拔除尿管恢复排尿,不需输血,IPSS由25.4±5.0降至10.3±2.4,膀胱残余尿量由184.7±43.6ml降至15.4±3.6ml,随访15～90天,平均34天,无排尿异常。结论此法治疗BHP近期效果满意,远期效果有待观察。     

肾母细胞瘤WT_1基因缺失

目的　对 30例散发性肾母细胞瘤WT1基因缺失进行检测 ,并分析其与组织类型的关系。方法　采用Southern印迹分子杂交技术。结果　 2例WT1基因内缺失为间质优势型肾母细胞瘤。结论　肾母细胞瘤的病因学十分复杂 ,WT1基因缺失可能与间质优势型肾母细胞瘤的发生有关。     

肾移植术后环孢素A血药浓度C2监测

目的:探讨术后存活期1 a以上的肾移植患者C2(服用环孢素(CsA)2 h后的血药浓度监测的临床效果.方法:术后存活期1 a以上、接受微乳化CsA(6～8 mg/(kg·d))、硫唑嘌呤和泼尼松三联免疫抑制治疗的患者75例,采用荧光偏振免疫方法进行CsA全血药浓度测定.C2监测至少6个月,CsA治疗窗浓度范围定为(900±120) μg/L.结果:C2监测前,46例(61%)患者CsA全血浓度高于目标浓度范围,13例(17%)低于目标浓度范围.C2监测6个月后,与C2监测前比较患者的尿素氮降低(P＜0.05,而血清肌酐、胆固醇和甘油三酯水平差异无统计学意义(P＞0.05);CsA平均剂量从(241±63 mg 减至(213±50) mg (P＜0.05), 每人每年节省费用约3 500元;C2监测6个月后,CsA暴露量过高患者组的BUN 水平较监测前降低(P＜0.05.结论:稳定期肾移植患者实行C2监测安全、有效.这种方法有利于肾功能的改善并有助于减少药品费用.